Cardiodermatology in the physician’s practice

Abstract

Cardiovascular diseases are the leading cause of hospitalization and mortality across the world. In 2013, the estimated number of deaths from cardiovascular diseases exceeded 17 million, accounting for 31.5% of all deaths globally, i.e. twice the number of all cancer-related deaths The article explores the correlation between selected dermatological diseases and an elevated risk of cardiovascular events. In addition, cutaneous manifestations of cardiovascular diseases which are important in the physician's practice, and therapeutic dilemmas involved in the coexistence of cardiac and dermatological diseases, are discussed. streszczenie Choroby układu sercowo-naczyniowego stanowią główną przyczynę hospitalizacji i zgonów na świecie. W 2013 roku liczbę zgonów z powodu chorób układu krążenia oszacowano na ponad 17 milionów, co stanowiło 31,5% ogółu zgonów na świecie, dwukrotnie przewyższając liczbę zgonów z powodu chorób nowotworowych. W artykule przeanalizowano związek wybranych chorób dermatologicznych ze zwiększonym ryzykiem wystąpienia incydentów sercowo-naczyniowych. Ponadto przedstawiono ważne z praktycznego punktu widzenia skórne objawy chorób układu krążenia oraz dylematy terapeutyczne w przypadku współistnienia chorób kardiologicznych i dermatologicznych.

Assessment of potential drug-to-drug interaction with antifungal agents in men with cardiovascular disease – a cross-sectional study of Polish population

“…However, it seems that the most common dermatological problem, even in the primary care physicians' o ce, are super cial mycotic infections. [4]. Super cial mycoses still seem to be an underdiagnosed problem; last available data for Polish population show a prevalence of approximately 15% [5].…”

Adalimumab and methotrexate affect the concentrations of regulatory cytokines (interleukin‐10, transforming growth factor‐β1, and interleukin‐35) in patients with plaque psoriasis

“…In psoriasis, T cell differentiation from CD4 + naïve cells is determined by the activity of specific transcription factors and cytokine secretion by dendritic cells, whereas in atherosclerosis, endothelial activation and its consequences drive this process 1‐3 . Treg lymphocytes affect other immune cells via direct cytotoxic activity or by secreting cytokines (ie, interleukin [IL]‐10, IL‐35, and transforming growth factor [TGF]‐β), which subsequently target cell signaling through cell membrane receptors 4‐6 . Reduced Treg concentrations contribute to the activation of Th1 and Th17 cells, leading to angiogenesis, keratinocyte activation, proliferation, and growth (Th1) in psoriasis as well as atherosclerotic plaque instability and rupture (Th17) 1‐3 .…”

“…Proinflammatory mediators, such as tumor necrosis factor alpha (TNF‐α), exert effects that contribute to the development of atherosclerosis. In contrast, IL‐10 and TGF‐β, as anti‐inflammatory mediators, reduce the risk of atherosclerosis development, limiting the possibility of severe complications 6,7 . The 10‐year risk of fatal cardiovascular disease estimated from the European Systematic Coronary Risk Evaluation (SCORE) risk chart can be used to predict the existence and severity of coronary atherosclerosis 8,9 …”

“…In contrast, IL-10 and TGF-β, as antiinflammatory mediators, reduce the risk of atherosclerosis development, limiting the possibility of severe complications. 6,7 The 10-year risk of fatal cardiovascular disease estimated from the European Systematic Coronary Risk Evaluation (SCORE) risk chart can be used to predict the existence and severity of coronary atherosclerosis. 8,9 IL-10 is a cytokine that primarily regulates immune and epithelial cells.…”